MCL1 and diffuse large B-cell lymphoma: Therefore, the combination of venetoclax with strategies targeting BCL-XL and MCL1, such as PI3K delta inhibitor idelalisib, seems to be promising, where synergizing effects have been observed in DLBCL cell lines and in vivo mouse models [150,151].